title: Lymphoproliferative disease of the ocular adnexa: a clinical and pathologic study with statistical analysis of 69 patients.
abstract: OBJECTIVE
  To evaluate the clinical features, treatment, and outcomes of a cohort of patients with ocular adnexal lymphoproliferative disease classified according to the World Health Organization modification of the Revised European-American Classification of Lymphoid neoplasms and to perform a robust statistical analysis of these data.
  
  
  METHODS
  Sixty-nine cases of ocular adnexal lymphoproliferative disease, seen in a tertiary referral center from 1992 to 2003, were included in the study. Lesions were classified by using the World Health Organization modification of the Revised European-American Classification of Lymphoid neoplasms classification. Outcome variables included disease-specific survival, relapse-free survival, local control, and distant control.
  
  
  RESULTS
  Stage IV disease at presentation, aggressive lymphoma histology, the presence of prior or concurrent systemic lymphoma at presentation, and bilateral adnexal disease were significant predictors for reduced disease-specific survival, local control, and distant control. Multivariate analysis found that aggressive histology and bilateral adnexal disease had significantly reduced disease-specific survival.
  
  
  CONCLUSIONS
  The typical presentation of adnexal lymphoproliferative disease is with a painless mass, swelling, or proptosis; however, pain and inflammation occurred in 20% and 30% of patients, respectively. Stage at presentation, tumor histology, primary or secondary status, and whether the process was unilateral or bilateral were significant variables for disease outcome. In this study, distant spread of lymphoma was lower in patients who received greater than 20 Gy of orbital radiotherapy.
authors.affiliation: Eyelid, Lacrimal and Orbital Clinic, Division of Ophthalmology, Department of Surgery, Royal Brisbane Hospital, Queensland, Australia. tjs@gil.com.au
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Sullivan
authors.forename: Kevin
authors.initials: K
authors.lastname: Whitehead
authors.forename: Richard
authors.initials: R
authors.lastname: Williamson
authors.forename: David
authors.initials: D
authors.lastname: Grimes
authors.forename: David
authors.initials: D
authors.lastname: Schlect
authors.forename: Ian
authors.initials: I
authors.lastname: Brown
authors.forename: Graeme
authors.initials: G
authors.lastname: Dickie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003131:Combined Modality Therapy; D003230:Conjunctival Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018572:Disease-Free Survival; D005134:Eye Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005142:Eyelid Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007766:Lacrimal Apparatus Diseases / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008223:Lymphoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate